EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Mucosal antibody responses following Vaxzevria vaccination

Kevin J Selva, Pradhipa Ramanathan, Ebene R Haycroft, Chee Wah Tan, Lin-Fa Wang, Laura E Downie, Samantha K Davis, Ruth A Purcell, Helen E Kent, Jennifer A Juno iD, Adam K Wheatley, Miles P Davenport and 2 more

Immunology & Cell Biology · 2023

DOI: 10.1111/imcb.12685 ↗

At a glance

Journal article in Immunology & Cell Biology, 2023. Written by Kevin J Selva and 13 co-authors. Institution: Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia. Major MEDLINE topics: COVID-19 Vaccines, COVID-19. Cited 7 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, National Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Mucosal antibodies play a key role in protection against breakthrough COVID‐19 infections and emerging viral variants. Intramuscular adenovirus‐based vaccination (Vaxzevria) only weakly induces nasal IgG and IgA responses, unless vaccinees have been previously infected. However, little is known about how Vaxzevria vaccination impacts the ability of mucosal antibodies to induce Fc responses, particularly against SARS‐CoV‐2 variants of concern (VoCs). Here, we profiled paired mucosal (saliva, tears) and plasma antibodies from COVID‐19 vaccinated only vaccinees (uninfected, vaccinated) and COVID‐19 recovered vaccinees (COVID‐19 recovered, vaccinated) who both received Vaxzevria vaccines. SARS‐CoV‐2 ancestral‐specific IgG antibodies capable of engaging FcγR3a were significantly higher in the mucosal samples of COVID‐19 recovered Vaxzevria vaccinees in comparison with vaccinated only vaccinees. However, when IgG and FcγR3a engaging antibodies were tested against a panel of SARS‐CoV‐2 VoCs, the responses were ancestral‐centric with weaker recognition of Omicron strains observed. In contrast, salivary IgA, but not plasma IgA, from Vaxzevria vaccinees displayed broad cross‐reactivity across all SARS‐CoV‐2 VoCs tested. Our data highlight that while intramuscular Vaxzevria vaccination can enhance mucosal antibodies responses in COVID‐19 recovered vaccinees, restrictions by ancestral‐centric bias may have implications for COVID‐19 protection. However, highly cross‐reactive mucosal IgA could be key in addressing these gaps in mucosal immunity and may be an important focus of future SARS‐CoV‐2 vaccine development.

Subjects

MeSH terms (MEDLINE)

COVID-19 VaccinesCOVID-19VaccinationAntibodies, ViralAntibody FormationHumansImmunoglobulin AAntibodies, NeutralizingChAdOx1 nCoV-19Breakthrough InfectionsImmunoglobulin G

Author keywords

COVID-19SARS-CoV-2Vaxzevriaantibodiessalivatears

Substances

COVID-19 VaccinesChAdOx1 nCoV-19Antibodies, ViralImmunoglobulin AImmunoglobulin GAntibodies, Neutralizing

Authors and institutions

  • Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
  • Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Singhealth Duke-NUS Global Health Institute, Singapore.
  • Department of Optometry and Vision Sciences, University of Melbourne, Carlton, VIC, Australia.
  • Kirby Institute, University of New South Wales, Kensington, NSW, Australia.

ORCID profiles: Jennifer A Juno, Stephen J Kent, Amy W Chung

Funding

  • National Health and Medical Research Council
  • National Medical Research Council

Cite

APA

Selva, K. J., Ramanathan, P., Haycroft, E. R., Tan, C. W., Wang, L. F., Downie, L. E., Davis, S. K., Purcell, R. A., Kent, H. E., Juno, J. A., Wheatley, A. K., Davenport, M. P., Kent, S. J., & Chung, A. W. (2023). Mucosal antibody responses following Vaxzevria vaccination. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12685

Vancouver

Selva KJ, Ramanathan P, Haycroft ER, Tan CW, Wang LF, Downie LE, et al. Mucosal antibody responses following Vaxzevria vaccination. Immunology & Cell Biology. 2023. doi:10.1111/imcb.12685

BibTeX
@article{Selva2023,
  author = {Selva, Kevin J and Ramanathan, Pradhipa and Haycroft, Ebene R and Tan, Chee Wah and Wang, Lin-Fa and Downie, Laura E and Davis, Samantha K and Purcell, Ruth A and Kent, Helen E and Juno, Jennifer A and Wheatley, Adam K and Davenport, Miles P and Kent, Stephen J and Chung, Amy W},
  title = {Mucosal antibody responses following Vaxzevria vaccination},
  journal = {Immunology & Cell Biology},
  year = {2023},
  doi = {10.1111/imcb.12685}
}
Start for free →